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Abstract: Osteomyelitis is responsible for high treatment costs, long hospital stays, and 
results in substantial morbidity. Treatment with surgical debridement and  
antibiotic-impregnated Polymethylmetacrylate (PMMA) beads is the standard of care, 
providing high local but low serum antibiotic concentrations, thereby avoiding systemic 
toxicity. However, for several reasons, the beads require surgical removal. Alternative 
antibiotic delivery systems should improve the treatment of bone infection, actively 
encourage bone healing and require no additional surgery for removal. We investigated the 
activity of gentamicin-loaded bioabsorbable beads against different microorganisms 
(Staphylococcus epidermidis, S. aureus, Escherichia coli, Enterococcus faecalis, Candida 
albicans) commonly causing surgical site bone infection, by microcalorimetry. Calcium 
sulphate beads containing gentamicin were incubated in microcalorimetry ampoules 
containing different concentrations of the corresponding microorganism. Growth medium 
with each germ and unloaded beads was used as positive control, growth medium with 
loaded beads alone as negative control. Bacterial growth-related heat production at 37 °C 
was measured for 24 h. Cultures without gentamicin-loaded beads produced heat-flow 
peaks corresponding to the exponential growth of the corresponding microorganisms in 
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nutrient-rich medium. In contrast, cultures with gentamicin-loaded beads completely 
suppressed heat production during 24 h, demonstrating their antibiotic activity. 
Gentamicin-loaded beads effectively inhibited growth of susceptible microorganisms, 
under the described in vitro conditions. 
Keywords: osteomyelitis; bone graft substitute; antibiotic-loaded bioabsorbable beads; 
microcalorimetry 
 
1. Introduction 
Perioperative antimicrobial prophylaxis, improved surgical technique and laminar airflows in the 
operating rooms have diminished the infection rate after internal fixation. However, it still remains 
approximately 0.5%–2% in closed fractures [1], and up to 30% in Grade III open fractures [2]. This is 
due to the risk of the implant and the peri-implant tissue becoming infected by pathogens or 
opportunistic bacteria [3,4]. As the number of implanted devices is constantly rising, the absolute 
number of implant-related infections is also increasing [5], and is, together with osteomyelitis, 
responsible for high treatment costs, long hospital stays, and often result in substantial morbidity [6].  
The standard treatment of osteomyelitis is a combination of surgical debridement and antimicrobial 
therapy [7]. Conventional systemic delivery of antibiotics is problematic because of its systemic 
toxicity with associated renal and liver complications [8,9] and poor antibiotic penetration into 
ischemic and necrotic tissue (often present in osteomyelitis). In addition, bacteria present in biofilms in 
the bone or on the implant can be up to 1000 times more resistant to most antimicrobial substances 
than their planktonic counterparts [10]. Local delivery of antibiotics was already initiated in the 1930s 
with the appearance of the sulfonamides, but with the arrival of Polymethylmetacrylate (PMMA), 
Buchholz and Engelbrecht [11] established in the 1970s, the principle of using antibiotic-impregnated 
bone cement to increase local antibiotic concentration, and thereby enhancing systemic antimicrobial 
therapy. In 1976, Marks et al. [12] proved that oxacillin, cefazolin and gentamicin are each released 
from acrylic bone cement in a microbiologically active form, and Elson et al. [13] showed that if depot 
PMMA antibiotics are introduced in bone, their concentration in bone is much higher than what can be 
achieved by safe intravenous administration.Unfortunately, several concerns about the use of PMMA 
as a delivery vehicle for depot antibiotics have risen. Retained PMMA acts as a foreign body once the 
release of the antibiotic has fallen below therapeutic levels, and the presence of prolonged 
subtherapeutic levels increases the risk of emergence of bacteria resistant to the antibiotic [14]. In 
addition, the porous PMMA represents an optimal surface for bacterial biofilm formation [15]. 
Moreover, in situations where large bony defects remain after the debridement, filling these defects 
with PMMA prevents the bone from healing. Removal of the PMMA depot, with subsequent bone 
grafting where necessary, is therefore generally advocated as soon as the infection is controlled, 
requiring a second surgical intervention [16].  
Alternative materials to PMMA for the delivery of depot antibiotics should therefore exhibit a faster 
and more complete release of the contained antibiotic to diminish the risk of resistance  
development [17]. In addition, the material should be biodegradable or capable of being incorporated 
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into the regenerating bone in order to avoid another surgical intervention for their removal. Bone graft 
substitutes have already been widely investigated as their implantation combines the possibility to 
deliver local antibiotics at high concentrations and simultaneously participate in the bone regeneration 
process [18,19]. Calcium sulphate (CaSO4) has been used since 1892 as a bone defect filler [19–21], 
preventing the ingrowth of soft tissue. It provides an osteoconductive matrix for the ingrowth of blood 
vessels and osteogenic cells that will reabsorb the CaSO4 while forming new bone [22,23]. It is 
probably the most frequent bone graft substitute used in the clinical setting of bone infection treatment, 
also because it is commercially available under different forms. Several authors already demonstrated 
the in vitro antibacterial activity of gentamicin-loaded plaster of Paris beads on bacterial  
cultures [24,25]. In a study from Sulo [26] gentamicin-loaded plaster beads were used since 1984 as a 
bone void filler in 409 patients with chronic osteomyelitis, with 96.5% of them cured, and a filling of 
bone loss of 50% and more occurring in 81.5%. In these studies the beads were fabricated in an 
artisanal fashion, the gentamicin powder being hand-mixed into the plaster, a time-consuming and 
inexact procedure. Several in vitro and in vivo studies have been performed with commercially 
available tobramycin-laden calcium sulphate beads [27–29], with a high efficacy rate. To our 
knowledge, no study investigating the antibacterial effect of a commercially available,  
gentamicin-loaded calcium-sulphate bone graft substitute has been published so far, although 
gentamicin has been, and still is, a widely used antibiotic for local delivery in the treatment of bone 
infection [30–32]. 
2. Objectives 
We investigated the in vitro activity of gentamicin-loaded bioabsorbable beads against different 
microorganisms commonly causing surgical site bone infection, by microcalorimetry. We expect that 
these beads will exhibit a strong antibacterial local effect against microorganisms susceptible to 
gentamicin, whereas the growth of germs not susceptible to gentamicin should not be affected.  
3. Results and Discussion 
Figure 1 illustrates the heat produced by S. aureus (A), S. epidermidis (B), E. faecalis (C),  
E. coli (D) and C. albicans (E) in the presence of calcium-sulphate beads with or without (control) 
gentamicin for 24 h.  
Beads were challenged with exponentially growing bacteria in concentrations of 10
5
, 10
6
 and 10
7
 
CFU/mL. An initial heat-flow was detected for all microorganisms (heat flow exceeding 20 μW) 
within 1 h independently of the presence of gentamicin. Nevertheless, as shown in Figure 1F, the 
initial heat is produced from a chemical reaction between the calcium-sulphate bead and the growth 
media, and is not a result of bacterial growth. A heat-flow peak of 68 μW and 45 μW, was observed 
for the gentamicin-loaded and the control bead (negative controls), respectively. Whereas the  
heat-producing reaction between the unloaded control bead and the media only lasted 4 h, the reaction 
between the gentamicin-loaded bead and the media continued for 24 h. 
By including a gentamicin non-susceptible microorganism in the study, C. albicans, heat produced 
by microbial growth could be distinguished from the background heat produced from the chemical 
reaction between the bead and the media. As shown in Figure 1E, C. albicans continued to produce 
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heat over 24 h with a stable heat signal of ~80–100 μW. In contrast, for the different  
gentamicin-susceptible bacterial species tested, the heat-production decreased during 24 h, indicating 
that the bacteria were not able to grow (Figure 1A–D). The gentamicin-loaded beads were able to 
inhibit the highest bacterial load tested (10
7
 CFU/mL) for all bacterial species tested. Control beads 
exhibited no antibacterial effect. In the presence of an unloaded control bead the bacterial heat-flow 
continued to rise exponentially until the heat-flow peak was reached. The heat-flow peak is reached 
when the microorganisms stop to actively divide and enter the stationary growth-phase, due to the lack 
of nutrients or oxygen.  
Figure 1. Thermokinetic profiles of S. aureus (A); S. epidermidis (B); E. faecalis (C); 
E. coli (D) and C. albicans (E) in the presence of calcium-sulphate beads with or without 
(positive control) gentamicin. Beads in growth media without microorganisms served as 
negative control (F). 
 
Table 1 describes the heat-flow peaks for the tested microorganisms in the presence of a control 
bead or a gentamicin-loaded bead, and the time-to-peak for the controls.  
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Table 1. Heat-flow peaks for tested microorganisms in the presence of gentamicin-loaded 
or control calcium-sulphate beads. 
Heat-flow peaks 
Control Gentamicin 
Peak (μW) Time to peak (h) Peak (μW) 
Concentration (cfu/mL) 107 106 105 107 106 105 107 106 105 
S. epidermidis 111 102 98 7.1 8.2 9.4 0 0 0 
S. aureus 184 175 183 4.4 4.9 5.7 8 0 0 
E. faecalis 335 285 285 3.1 4.1 4.6 8 3 0 
E. coli 375 325 338 3.4 3.9 5.2 12 0 0 
C. albicans * 249 240 239 24 24 24 53 51 32 
* Fungal concentrations tested were 105,104 and 103 CFU/mL. 
The heat-flow peak of the negative controls was deduced for the control and the gentamicin beads, 
respectively. For control beads, a proportional delay in time-to-peak was observed with decreasing 
bacterial concentrations. When comparing the heat-flow peaks, corresponding to the total number of 
active cells, a nearly 100% reduction was observed in the presence of gentamicin in comparison to the 
control beads, for S. epidermidis, S. aureus, E. faecalis and E. coli, respectively. Only in the presence 
of the highest bacterial inoculum some heat was produced. In contrast, for C. albicans heat-flow peaks 
ranging from 51 to 53 μW were observed (after substracting the background heat produced by the  
bead alone.) 
Microcalorimetry is an innovative method based on measuring heat from replicating 
microorganisms in culture. It was first evaluated as a rapid and accurate screening method for 
contaminated platelet concentrates [33]. The heat flow is proportional to the quantity of bacteria and 
can be used for quantitative assessment [34]. For planktonic bacteria, it is now widely used as a  
non-invasive [35] monitoring instrument due to its high sensitivity, reproducibility and simplicity [36]. 
In our experiment measures obtained by microcalorimetry indicated a nearly 100% reduction of the 
heat-flow peaks for all the bacterial species in the presence of gentamicin, in comparison to the control 
beads, which proved that the gentamicin-loaded beads effectively inhibited even the highest bacterial 
load tested for all the gentamicin-susceptible bacterial species they were challenged with, clearly 
demonstrating their antibiotic activity. Our findings correlate thus with the results of Mackey et al. [24] 
and Mousset et al. [25], who already demonstrated the in vitro antibacterial activity of  
gentamicin-loaded plaster of Paris beads on bacterial cultures. 
Interestingly, when comparing the heat-flow peak of C. albicans reached in the presence or absence 
of gentamicin, a clear reduction in growth-related heat was observed in the presence of the  
antibiotic-loaded bead, although C. albicans is a gentamicin non-susceptible microorganism. As shown 
by Wichelhaus et al. [32] and by Kluin et al. [37], calcium-sulphate carriers normally exhibit an 
in vitro burst-release, mostly caused by diffusion, of gentamicin within the first 24 h (approximately 
80%), followed by a more gradual release over a period of at least 10 days. Considering the gentamicin 
loading of 2.5 mg per bead, gentamicin concentrations above 500 µg/mL could be expected in the 
calorimetric ampoule. Short-duration high-concentration levels at the infection site are desirable for 
antibiotics such as aminoglycosides that increase their effectiveness with increasing concentration 
(dose-dependent killing of bacteria) [38]. As gentamicin serum levels above 12 µg/mL are considered 
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toxic [39] (when monitoring therapeutic drug levels), the observed decrease in heat produced by  
C. albicans is most likely induced by the high gentamicin concentration in the growth media. This could 
become a major issue in the clinical setting, as local antibiotic delivery vehicles diminish systemic 
toxicity at the price of higher local toxicity [40]. Isefuku et al. [41] demonstrated that high local 
concentrations of antibiotics may alter the bone regeneration process, with gentamicin concentrations 
exceeding 100 µg/mL significantly decreasing alkaline phosphatase activity and 
3
H-thymidine 
incorporation, while concentrations above 700 µg/mL also decreased total DNA in a study on human 
osteoblast-like cells. Hanssen et al. [42] postulated that the benefits of high local antibiotic 
concentrations for infection eradication need to be balanced against the potentially negative effects on 
the bone regeneration processes which often occupy a considerable place in the treatment of 
musculoskeletal infection. 
Another major issue with local antibiotic delivery vehicles is the fact that there is no correlation 
between in vitro and in vivo elution parameters, several studies evaluating calcium sulphate showing 
considerably longer release duration in animal models than in elution studies [27,43]. For  
McLaren [17], fluid dynamics in the animal model seem to be more restricted than in the elution bath, 
and the elution parameters do not accurately reproduce the environment of a wound. Moreover, release 
characteristics of each preparation of antibiotic delivery vehicle are specific to that preparation. The 
next step of our investigations will be the determination of the in vitro elution kinetics of gentamicin 
from the investigated calcium sulphate beads in order to verify if the elution profiles are consistent 
with the ones found by Wichelhaus [32] and Kluin [37], respectively. 
Subsequently, standardized in vivo investigations that accurately reproduce the clinical wound 
environment should be carried out, including important variables such as site of implantation 
(intramedullary or soft tissue), implant size, concentration of contained antibiotic, etc., to determine 
the expected clinical performance before clinical studies can be initiated.  
4. Experimental Section  
4.1. Bone Graft Substitute 
Herafill
®
 beads G (Heraeus Medical, Hanau, Germany), biconvex rounded cylindrical beads  
(250 mg, 6 mm diameter) consisting essentially of calcium sulphate dihydrate, and containing 
gentamicin (2.5 mg equivalent 1%, in form of gentamicin sulphate), were used. They are indicated to 
fill bone voids that result from surgical debridement of bone infections, and are supposed to enhance 
antibiotic protection and encourage bone growth. 
Osteoset
®
 beads, obtained from an Osteoset Resorbable Mini-Bead Kit-Fast Cure 5cc (Wright 
Medical Technology, Arlington, TN, USA), cylindrical beads (100 mg, 4.8 mm diameter) consisting 
essentially of calcium sulphate hemihydrate and containing no antibiotics, were used in the positive 
control group (unloaded bead plus microorganism). Osteoset
®
 beads are indicated to be used as 
osteoconductive material for the ingrowth of blood vessels and osteoprogenitor cells from the graft bed 
in the treatment of bone voids. 
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4.2. Study Organisms 
Laboratory strains of different microorganisms causing bone infection were studied, including 
Staphylococcus epidermidis RP62A (ATCC 35984), S. aureus (ATCC 29213), Escherichia coli 
(DH5α), Enterococcus faecalis (ATCC 19433) and Candida albicans (ATCC 90028). Strains were 
stored at −80 °C and cultured overnight on human blood agar plates before each experiment. 
4.3. Evaluation of Gentamicin Activity by Isothermal Microcalorimetry 
A bacterial or fungal suspension of McFarland 0.5 was prepared, corresponding to a density of  
10
6–108 colony-forming units (CFU)/mL depending on the microorganism. 4 mL sterile 
microcalorimetric glass ampoules were filled with 3 mL of Müller-Hinton broth (Sabouraud dextrose 
broth for C. albicans) and inoculated with three different inocula corresponding to final bacterial 
concentrations of 10
5
, 10
6
 and 10
7
 CFU/mL. C. albicans was tested in concentrations of 10
3
, 10
4 
and 
10
5
 CFU/mL. Microorganisms were incubated 2 h at 37 °C in order to initiate the exponential  
growth phase.  
After the incubation, one bead, with or without gentamicin, was transferred to each ampoule. An 
ampoule containing a bead and media only served as negative control. All ampoules were closed with 
a rubber cap, sealed by manual crimping and sequentially introduced into the calorimetry instrument. 
After 15 min in the thermal equilibration position, ampoules were lowered into the measurement 
position. Heat flow was measured for up to 24 h at 10 s intervals. A 48-channel batch calorimeter 
(thermal activity monitor, model 3102 TAM III; TA Instruments, New Castle, DE, USA) was used to 
measure the heat flow at 37 °C controlled at 0.0001 °C and a sensitivity of 0.2 μW. Heat was measured 
continuously and expressed as heat flow over time (in microwatts (μW)). Calorimetric detection time 
was defined as the time from insertion of the ampoule into the calorimeter until an exponentially rising 
heat flow signal exceeding 20 μW was detected.  
Data collection was performed using the calorimeter manufacturer’s software. Data was processed 
in Prism software, version 5.0a (GraphPad Software, La Jolla, CA, USA).  
5. Conclusions 
The gentamicin-loaded bioabsorbable calcium sulphate beads investigated in this study effectively 
inhibited growth of gentamicin-susceptible microorganisms, under the described in vitro conditions. 
Standardized animal studies are mandatory to determine the elution kinetics and the antibacterial effect 
of gentamicin under in vivo conditions. Finally, clinical studies are needed to demonstrate that 
treatment against bone infection with the use of commercially available gentamicin-loaded 
bioabsorbable calcium sulphate beads is a good therapeutic option. 
Conflict of Interest 
The authors declare no conflict of interest. 
  
Materials 2013, 6 3291 
 
 
References 
1. Trampuz, A.; Zimmerli, W. Diagnosis and treatment of implant-associated septic arthritis and 
osteomyelitis. Curr. Infect. Dis. Rep. 2008, 10, 394–403. 
2. Ostermann, P.A.; Henry, S.L.; Seligson, D. Timing of wound closure in severe compound 
fractures. Orthopedics 1994, 17, 397–399. 
3. Arciola, C.R.; Campoccia, D.; An, Y.H.; Baldassarri, L.; Pirini, V.; Donati, M.E.; Pegreffi, F.; 
Montanaro, L. Prevalence and antibiotic resistance of 15 minor staphylococcal species colonizing 
orthopedic implants. Int. J. Artif. Organs 2006, 29, 395–401. 
4. Von Eiff, C.; Arciola, C.R.; Montanaro, L.; Becker, K.; Campoccia, D. Emerging Staphylococcus 
species as new pathogens in implant infections. Int. J. Artif. Organs 2006, 29, 360–367. 
5. Del Pozo, J.L.; Patel, R. The challenge of treating biofilm-associated bacterial infections.  
Clin. Pharmacol. Ther. 2007, 82, 204–209. 
6. Mabry, R.L.; Holcomb, J.B.; Baker, A.M.; Cloonan, C.C.; Uhorchak, J.M.; Perkins, D.E.; 
Canfield, A.J.; Hagmann, J.H. United States Army Rangers in Somalia: An analysis of combat 
casualties on an urban battlefield. J. Trauma 2000, 49, 515–528; discussion 528–529. 
7. Cierny, G., Ш; Mader, J.T.; Penninck, J.J. A clinical staging system for adult osteomyelitis. Clin. 
Orthop. Relat. Res. 2003, 414, 7–24. 
8. Conterno, L.O.; da Silva Filho, C.R. Antibiotics for treating chronic osteomyelitis in adults. 
Cochrane. Database Syst. Rev. 2009, doi:10.1002/14651858.CD004439.pub2. 
9. Hermsen, E.D.; Hanson, M.; Sankaranarayanan, J.; Stoner, J.A.; Florescu, M.C.; Rupp, M.E. 
Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during 
treatment of deep-seated infections. Expert. Opin. Drug Saf. 2010, 9, 9–14. 
10. Donlan, R.M. Biofilms: Microbial life on surfaces. Emerg. Infect. Dis. 2002, 8, 881–890. 
11. Buchholz, H.W.; Engelbrecht, H. Über die Depotwirkung einiger Antibiotika bei Vermischung 
mit dem Kunstharz Palacos (in German). Chirurg 1970, 41, 511–515. 
12. Marks, K.E.; Nelson, C.L.; Lautenschlager, E.P. Antibiotic-impregnated acrylic bone cement.  
J. Bone Joint Surg. Am. 1976, 58, 358–364. 
13. Elson, R.A.; Jephcott, A.E.; McGechie, D.B.; Verettas, D. Antibiotic-loaded acrylic cement.  
J. Bone Joint Surg. Br. 1977, 59, 200–205. 
14. Neut, D.; van de Belt, H.; van Horn, J.R.; van der Mei, H.C.; Busscher, H.J. Residual  
gentamicin-release from antibiotic-loaded polymethylmethacrylate beads after 5 years of 
implantation. Biomaterials 2003, 24, 1829–1831. 
15. Kendall, R.W.; Duncan, C.P.; Smith, J.A.; Ngui-Yen, J.H. Persistence of bacteria on antibiotic 
loaded acrylic depots. A reason for caution. Clin Orthop Relat Res. 1996, 329, 273–280. 
16. Buchholz, H.W.; Elson, R.A.; Heinert, K. Antibiotic-loaded acrylic cement: current concepts. 
Clin. Orthop. Relat. Res. 1984, 190, 96–108. 
17. McLaren, A.C. Alternative materials to acrylic bone cement for delivery of depot antibiotics in 
orthopaedic infections. Clin. Orthop. Relat. Res. 2004, 427, 101–106. 
18. Cornell, C.N.; Tyndall, D.; Waller, S.; Lane, J.M.; Brause, B.D. Treatment of experimental 
osteomyelitis with antibiotic-impregnated bone graft substitute. J. Orthop. Res. 1993, 11,  
619–626. 
Materials 2013, 6 3292 
 
 
19. Greenwald, A.S.; Boden, S.D.; Goldberg, V.M.; Khan, Y.; Laurencin, C.T.; Rosier, R.N. 
American Academy of Orthopaedic Surgeons. The Committee on Biological, I. Bone-graft 
substitutes: Facts, fictions, and applications. J. Bone Joint Surg. Am. 2001, 83-A Suppl 2 Pt 2,  
98–103. 
20. Dreesmann, H. Über Knochenplombierung (in German). Beitr. Klin. Chir. 1892, 9, 804–810. 
21. Kelly, C.M.; Wilkins, R.M.; Gitelis, S.; Hartjen, C.; Watson, J.T.; Kim, P.T. The use of a surgical 
grade calcium sulfate as a bone graft substitute: Results of a multicenter trial. Clin. Orthop. Relat. 
Res. 2001, 382, 42–50. 
22. Sidqui, M.; Collin, P.; Vitte, C.; Forest, N. Osteoblast adherence and resorption activity of 
isolated osteoclasts on calcium sulphate hemihydrate. Biomaterials 1995, 16, 1327–1332. 
23. Turner, T.M.; Urban, R.M.; Gitelis, S.; Infanger, S.; Berzins, A.; Hall, D.J. Efficacy of calcium 
sulphate, a synthetic bone graft material, in healing a large canine medullary defect. In 
Proceesings of the 45th Annuual Meeting, Orethopedic Research Society, Anaheim, CA, USA,  
1–4 February 1999; Abstract 522. 
24. Mackey, D.; Varlet, A.; Debeaumont, D. Antibiotic loaded plaster of Paris pellets: An in vitro 
study of a possible method of local antibiotic therapy in bone infection. Clin. Orthop. Relat. Res. 
1982, 167, 263–268. 
25. Mousset, B.; Benoit, M.A.; Delloye, C.; Bouillet, R.; Gillard, J. Biodegradable implants for 
potential use in bone infection. An in vitro study of antibiotic-loaded calcium sulphate. Int. 
Orthop. 1995, 19, 157–161. 
26. Sulo, I. Gentamycin impregnated plaster beads in the treatment of bone infection. Rev. Chir. 
Orthop. Reparatrice Appar. Mot. 1993, 79, 299–305. 
27. Nelson, C.L.; McLaren, S.G.; Skinner, R.A.; Smeltzer, M.S.; Thomas, J.R.; Olsen, K.M. The 
treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium 
sulfate tobramycin pellets. J. Orthop. Res. 2002, 20, 643–647. 
28. McKee, M.D.; Wild, L.M.; Schemitsch, E.H.; Waddell, J.P. The use of an antibiotic-impregnated, 
osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects: 
early results of a prospective trial. J. Orthop. Trauma 2002, 16, 622–627. 
29. Beardmore, A.A.; Brooks, D.E.; Wenke, J.C.; Thomas, D.B. Effectiveness of local antibiotic 
delivery with an osteoinductive and osteoconductive bone-graft substitute. J. Bone Joint Surg. Am. 
2005, 87, 107–112. 
30. Klemm, K. Septopal—A new way of local antibiotic therapy. In Local Antibiotic Treatment in 
Osteomyelitis and Soft Tissue Infections; Van Rens, T.J.G., Kayser, F.H., Eds.; Excerpta Medica: 
Amsterdam, The Netherlands, 1981; pp. 24–37. 
31. Wahlig, H.; Dingeldein, E.; Bergmann, R.; Reuss, K. The release of gentamicin from 
polymethylmethacrylate beads. An experimental and pharmacokinetic study. J. Bone Joint Surg. 
Br. 1978, 60B, 270–275. 
32. Wichelhaus, T.A.; Dingeldein, E.; Rauschmann, M.; Kluge, S.; Dieterich, R.; Schafer, V.;  
Brade, V. Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from 
calcium sulphate beads. J. Antimicrob. Chemother. 2001, 48, 117–119. 
33. Trampuz, A.; Salzmann, S.; Antheaume, J.; Daniels, A.U. Microcalorimetry: A novel method for 
detection of microbial contamination in platelet products. Transfusion 2007, 47, 1643–1650. 
Materials 2013, 6 3293 
 
 
34. Clauss, M.; Trampuz, A.; Borens, O.; Bohner, M.; Ilchmann, T. Biofilm formation on bone grafts 
and bone graft substitutes: comparison of different materials by a standard in vitro test and 
microcalorimetry. Acta Biomater. 2010, 6, 3791–3797. 
35. Von Ah, U.; Wirz, D.; Daniels, A.U. Isothermal micro calorimetry—A new method for MIC 
determinations: results for 12 antibiotics and reference strains of E. coli and S. aureus. BMC 
Microbiol. 2009, doi:10.1186/1471-2180-9-106. 
36. Trampuz, A.; Steinhuber, A.; Wittwer, M.; Leib, S.L. Rapid diagnosis of experimental meningitis by 
bacterial heat production in cerebrospinal fluid. BMC Infect. Dis. 2007, doi:10.1186/1471-2334-7-116.  
37. Kluin, O.S.; van der Mei, H.C.; Busscher, H.J.; Neut, D. Biodegradable vs. non-biodegradable 
antibiotic delivery devices in the treatment of osteomyelitis. Expert Opin. Drug Deliv. 2013, 10, 
341–351. 
38. Craig, W.A. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of 
mice and men. Clin. Infect. Dis. 1998, 26, 1–10; quiz 11–12. 
39. Lerner, S.A.; Schmitt, B.A.; Seligsohn, R.; Matz, G.J. Comparative study of ototoxicity and 
nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am. J. 
Med. 1986, 80, 98–104. 
40. Miclau, T.; Edin, M.L.; Lester, G.E.; Lindsey, R.W.; Dahners, L.E. Bone toxicity of locally 
applied aminoglycosides. J. Orthop. Trauma 1995, 9, 401–406. 
41. Isefuku, S.; Joyner, C.J.; Simpson, A.H. Gentamicin may have an adverse effect on osteogenesis. 
J. Orthop. Trauma 2003, 17, 212–216. 
42. Hanssen, A.D. Local antibiotic delivery vehicles in the treatment of musculoskeletal infection. 
Clin. Orthop. Relat. Res. 2005, 437, 91–96. 
43. McLaren, A.C.; McLaren, S.G.; Nelson, C.L.; Wassell, D.L.; Olsen, K.M. The effect of sampling 
method on the elution of tobramycin from calcium sulfate. Clin. Orthop. Relat. Res. 2002, 403,  
54–57. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
